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C2238/αANP modulates apolipoprotein E through
Egr-1/miR199a in vascular smooth muscle cells in vitro
R Stanzione1,4, S Sciarretta1,2,4, S Marchitti1, F Bianchi1, S Di Castro1, S Scarpino3, M Cotugno1, G Frati1,2, M Volpe1,3 and S Rubattu*,1,3
Subjects carrying the T2238C ANP gene variant have a higher risk to suffer a stroke or myocardial infarction. The mechanisms
through which T2238C/αANP exerts detrimental vascular effects need to be fully clarified. In the present work we aimed at
exploring the impact of C2238/αANP (mutant form) on atherosclerosis-related pathways. As a first step, an atherosclerosis gene
expression macroarray analysis was performed in vascular smooth muscle cells (VSMCs) exposed to either T2238/αANP (wild
type) or C2238/αANP. The major finding was that apolipoprotein E (ApoE) gene expression was significantly downregulated by
C2238/αANP and it was upregulated by T2238/αANP. We subsequently found that C2238/αANP induces ApoE downregulation
through type C natriuretic peptide receptor (NPR-C)-dependent mechanisms involving the upregulation of miR199a-3p and
miR199a-5p and the downregulation of DNAJA4. In fact, NPR-C knockdown rescued ApoE level. Upregulation of miR199a by NPR-C
was mediated by a reactive oxygen species-dependent increase of the early growth response protein-1 (Egr-1) transcription factor.
In fact, Egr-1 knockdown abolished the impact of C2238/αANP on ApoE and miR199a. Of note, downregulation of ApoE by C2238/
αANP was associated with a significant increase in inflammation, apoptosis and necrosis that was completely rescued by the
exogenous administration of recombinant ApoE. In conclusion, our study dissected a novel mechanism of vascular damage
exerted by C2238/αANP that is mediated by ApoE downregulation. We provide the first demonstration that C2238/αANP
downregulates ApoE in VSMCs through NPR-C-dependent activation of Egr-1 and the consequent upregulation of miR199a.
Restoring ApoE levels could represent a potential therapeutic strategy to counteract the harmful effects of C2238/αANP.
Cell Death and Disease (2015) 6, e2033; doi:10.1038/cddis.2015.370; published online 31 December 2015
Atrial natriuretic peptide (ANP) plays important cytoprotective
cardiovascular functions, such as antihypertrophic, antiproli-
ferative and prosurvival effects in cardiomyocytes, vascular
smooth muscle cells (VSMCs), fibroblasts and endothelial
cells.1 Recent work demonstrated that a molecular variant of
αANP (C2238/αANP), which is characterized by the C-term-
inal extension of the peptide with two arginine residues and is
secondary to the substitution of a thymine for a cytosine at
position 2238 of the ANP gene, exerts detrimental vascular
effects. In fact, we and other groups previously showed that
subjects carrying the T2238C ANP gene variant have a
significantly higher risk to have a stroke or a myocardial
infarction and display a significant increase of circulating
markers of leukocyte activation.2–8 Overall, this evidence
highlights the need to find therapeutic targets to prevent or
reduce the detrimental effects of C2238/αANP gene variant,
which is relatively frequent in the general population. However,
this is possible only if the molecular mechanisms through
which C2238/αANP favors the development of vascular
dysfunction, atherosclerosis and cardiovascular accidents
are fully elucidated.
We previously reported that C2238/αANP molecular variant
promotes cellular apoptosis, necrosis and oxidative stress,
whereas it reduces cell proliferation, angiogenesis and
vasodilation.9–11 Mechanistically, we found that the deleter-
ious effects of C2238/αANP variant are mediated by a
deregulated activation of the type C natriuretic peptide
receptor (NPR-C) with a consequent decrease of cAMP levels
and PKA activity.10,11 The abnormal activation of NPR-C was
found to be associated with a reduction of the Akt/eNOS
pathway and an increase in NADPH oxidase-derived reactive
oxygen species (ROS) activity in endothelial cells.9,10 In
addition, an epigenetic phenomenon involving miR21 sig-
nificantly contributed to the detrimental effects of C2238C/
αANP on cell viability and function in VSMCs.11 However,
these molecular mechanisms can only explain the deleterious
properties of C2238/αANP on atherosclerotic plaque stability.
On the other hand, the interaction of C2238/αANP with
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multiple genes/proteins directly related to the atherosclerotic
process remains unknown. This latter possibility is supported
by the known involvement of natriuretic peptides in
atherosclerosis.1
For this reason, we conducted a gene expression macro-
array analysis in VSMCs, a key cellular element in athero-
sclerosis development12 and a target of ANP,1 in order to
investigate the potential impact of T2238C/αANP on mechan-
isms underlying atherosclerosis. We found that C2238/αANP
induces a significant downregulation of the apolipoprotein E
(ApoE) gene expression, encoding a known antiatherosclero-
tic and anti-inflammatory protein, through the activation of the
NPR-C/Egr-1/miR199a/DNAJA4 signaling pathway that we
dissect here for the first time. ApoE downregulation was found
to be responsible for the detrimental cellular abnormalities
induced by T2238C/αANP in VSMCs.
Results
Differential ApoE gene expression in VSMCs induced by
TT2238/αANP and CC2238/αANP. Atherosclerosis genes
expression profile of human umbilical vein smooth muscle
cells (HUVSMCs) exposed to either TT2238/αANP or
CC2238/αANP, compared with unstimulated cells, is reported
in Table 1. Among the sequences that were significantly
and differentially regulated (at least 5-fold) by the two αANP
forms, ApoE gene was significantly reduced by CC2238/
αANP, whereas it was markedly stimulated by TT2238/αANP.
We validated the macroarray results by demonstrating that
both ApoE mRNA and protein expression levels were
downregulated in both HUVSMCs (Figures 1a and b) and
coronary artery SMCs (CAMSCs) (Figures 1c and d)
by CC2238/αANP, whereas they were upregulated by
TT2238/αANP. Since it is well known that ApoE exerts critical
antiatherosclerotic and anti-inflammatory actions,13 we
decided to evaluate whether ApoE downregulation mediates
the detrimental effects of CC2238/αANP.
CC2238/αANP induces ApoE downregulation through
NPR-C-dependent mechanisms associated with the
upregulation of miR199a. We then dissected the mechan-
isms through which CC2238/αANP induces the reduction of
ApoE expression. Previous work from our laboratory
demonstrated that CC2238/αANP induces detrimental vas-
cular effects through a deregulated activation of NPR-C.10,11
Therefore, we investigated whether NPR-C mediates
the effects of CC2238/αANP on ApoE expression levels.
Our results confirmed this hypothesis, since we found that
NPR-C knockdown rescued ApoE expression levels
in both HUVSMCs and coronary artery smooth muscle
cells (CASMCs) exposed to CC2238/αANP (Figures 2a
and 3a).
Of note, previous evidence demonstrated that ApoE
expression levels are epigenetically regulated by miR199a-
3p and miR199a-5p, which in turn can either directly target
ApoE or target the heat-shock protein DNAJA4, which pro-
motes the upregulation of ApoE.14 In line with this evidence,
we found that miR199a-3p and miR199a-5p expression levels
are significantly upregulated by CC2238/αANP, whereas they
are downregulated by TT2238/αANP. On the other hand, the
DNAJA4 expression level resulted to be downregulated by
CC2238/αANP, whereas it was unchanged in cells exposed to
TT2238/αANP (Figures 2b and 3b). Interestingly, we observed
that NPR-C knockdown rescued miR199a-3p, miR199a-5p
and DNAJA4 expression levels in both VSMC lines treated
with CC2238/αANP (Figures 2b and 3b). These data suggest
that NPR-C regulates ApoE levels through the regulation of
miR199a-3p, miR199a-5p and DNAJA4.
NPR-C regulates miR199a through the ROS-depen-
dent activation of early growth response protein-1
(Egr-1). Then, we tried to elucidate the signaling mechan-
isms through which NPR-C promotes the upregulation of
miR199a-3p and miR199a-5p, the downregulation of
DNAJA4 and ultimately the downregulation of ApoE expres-
sion levels in response to CC2238/αANP. The transcription
factor Egr-1 was previously found to promote the upregulation
of miR199a.15 In addition, Egr-1 is often found activated in the
vasculature during stress and was described to be involved
in the atherosclerotic process.16 Therefore, we evaluated
whether Egr-1 is involved in the NPR-C-dependent regulation
of miR199a-3p and miR199a-5p in response to CC2238/
αANP. We found that Egr-1 is upregulated in response to
CC2238/αANP and this effect was abrogated by NPR-C
knockdown (Figures 2c and 3c). CC2238/αANP is known to
induce NPR-C-dependent NADPH oxidase activation and
ROS production.9,10 Egr-1 can be activated by ROS.17 In
accordance, we found that C2238/αANP-dependent upregu-
lation of Egr-1 was blunted by apocynin, a NADPH oxidase
inhibitor (Supplementary Figure S1). Finally, we found that
Egr-1 knockdown normalized miR199a and DNAJA4 levels
Table 1 Atherosclerosis genes that are modulated by TT2238/αANP and
CC2238/αANP versus control according to real time-PCR array
Gene name TT2238/αANP versus
Ctrl
CC2238/αANP versus
Ctrl
APOE 38.48±18.57 −6.66± 4.13
BCL2 9.37±3.84 −6.70± 1.94
BCL2A1 16.62±39.98 −1.13± 1
BCL2L1 24.24±14.69 133.34± 79.02
CCL2 −736.48±426.11 − 5514.23± 2765.44
CTGF −1.89±1 −12.14± 15.01
FGF2 − 40.18±19.21 0.29± 3.78
FN1 −1855.62±888.82 −0.97± 2.57
ITGA2 2.70±3.32 18.22± 7.09
ITGA5 −0.95±5.45 −20.05± 7.52
MMP3 10.57±7.79 21.57± 14.94
NOS3 − 24.76±1 −2.51± 1
PDGFB 8.07±4.96 0.04± 2.52
PPARD −6.05±1.87 −0.93± 1.94
PPARG −7.16±1.36 −4,57± 0,33
SERPINE1 −2.61±2.55 −5.84± 0,67
SOD1 −4.77±7.16 1.22± 3.20
TNC −109.95±63.82 −1.80± 2.52
TNF 6.04±5.03 −2.59± 6.53
Number of independent experiments= 3.
BCL2, B-cell lymphoma 2;CCL2, chemokine ligand 2;CTGF, connective tissue
growth factor; FGF2, fibroblast growth factor 2; FN1, fibronectin 1; ITGA2,
integrin alpha 2; ITGA5, integrin alpha 5; MMP3, matrix metallopeptidase 3;
NOS3, nitric oxide synthase 3; PDGFB, platelet-derived growth factor subunit B;
PPARD, PPARG, peroxisome proiliferator-activated receptor delta, gamma;
SERPINE1, serpin peptidase inhibitor; SOD1, superoxide dismutase 1; TNF,
tumor necrosis factor.
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and blocked the ApoE downregulation in both VSMC lines
treated with CC2238/αANP (Figure 4). Overall, these data
indicate that CC2238/αANP leads to miR199a upregulation
and ApoE downregulation in VSMCs through the NPR-C-
dependent ROS production which in turn leads to Egr-1
activation.
CC2238/αANP modulates apoptosis, necrosis and
inflammation in VSMCs through NPR-C-dependent ApoE
downregulation. Then, we evaluated the biological signifi-
cance of ApoE downregulation in cells exposed to CC2238/
αANP. Supplementary Figures S2 and S3 show the results of
western blotting analysis to evaluate the expression levels of
cleaved caspase-3, cellular repressor of E1A-stimulated
gene (CREG), and both phosphorylated and total forms of
JNK and p38MAPK in HUVSMCs (Supplementary Figure S2)
and in CASMCs (Supplementary Figure S3) in the presence
of CC2238/αANP. Cleaved caspase-3 was increased by
CC2238/αANP (Supplementary Figures S2A and S3A). On
the other hand, expression of CREG, an antiapoptotic factor,
was reduced (Supplementary Figures S2B and S3B).
Consistently with previous studies showing that CREG
inhibits VSMC apoptosis through the inhibition of p38MAPK
and JNK signaling pathways,18 we observed a parallel
increased phosphorylation of both p38MAPK and JNK in
both HUVSMCs and CASMCs treated with CC2238/αANP as
compared with control cells (Supplementary Figures S2C, D,
S3C and D). Of note, NPR-C knockdown completely rescued
the CC2238/αANP effects on cleaved-caspase-3, phospho-
p38MAPK, phosphoJNK and CREG. Cellular levels of NF-κB
and Smad4, known markers of inflammation, were also
significantly increased in both HUVSMCs and CASMCs
exposed to CC2238/αANP (Supplementary Figures S2E, F,
S3E and F). NPR-C gene silencing blunted the increase of
both NF-κB and Smad4 despite the presence of CC2238/
αANP in both VSMC lines (Supplementary Figures S2E, F,
S3E and F). Altogether, these findings indicate that C2238/
αANP induces apoptosis and inflammation in VSMCs through
NPR-C-dependent mechanisms.
Of note, we found that these mechanisms are mediated by
ApoE downregulation. First of all, sequencing analysis
revealed that HUVSMCs express the ApoE isoforms 2 and 3
(APOE2/APOE3) whereas CASMCs express ApoE isoforms
3 and 4 (APOE3/APOE4) (Supplementary Figure 4). More
importantly, we found that restoration of ApoE levels in both
HUVSMCs (Figure 5a) and CASMCs (Figure 5b) treated with
CC2238/αANP through the concomitant exogenous adminis-
tration of the corresponding ApoE recombinant isoform was
able to rescue cell viability, which was significantly impaired by
CC2238/αANP alone as compared with untreated cells. ApoE
administration significantly reduced both early and late
apoptosis and necrosis induced by CC2238/αANP. In addition,
VSMCs showed a significant decrease of inflammation under
exposure to recombinant ApoE despite the presence of
CC2238/αANP (Figure 6).
Discussion
T2238C/αANP gene variant is an emerging non-modifiable
cardiovascular risk factor. In fact, subjects carrying this genetic
variant have a higher risk for occurrence of cardiovascular
adverse events, such as stroke and myocardial infarction. In
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addition, these subjects display signs of endothelial dysfunc-
tion already at a young age. Here, we analyzed the impact of
the T2238C/αANP gene variant on atherosclerosis-related
mechanisms. We found that C2238/αANP significantly
downregulates ApoE gene expression in VSMCs through
NPR-C-dependent mechanisms. We also demonstrated that
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C2238/αANP plays this effect through a selective epigenetic
regulation of ApoE involving Egr-1 and two small noncoding
RNAs (miR199a-3p and miR199a-5p). Most importantly,
we provided evidence that the detrimental effects induced by
the C2238/αANP–NPR-C axis in VSMCs, such as increased
rate of apoptosis, necrosis and inflammation, could be fully
recovered by recombinant ApoE protein supplementation
(Figure 7).
These data significantly extend our previous evidence
demonstrating that C2238/αANP induces endothelial cell
death and oxidative stress, reduces angiogenesis and pro-
motes endothelial dysfunction through the deregulated activa-
tion of NPR-C/cAMP signaling and the reduction of the PKA/
Akt/eNOS pathway.9–10 In addition, we recently found that
C2238/αANP increases oxidative stress and cellular migration
and promotes vasoconstriction through the NPR-C/cAMP/
PKA/CREB/miR21 signaling pathway.11 The current study
demonstrates for the first time a direct impact of C2238/αANP
on mechanisms underlying atherosclerosis in VSMCs, a key
element in this process. In fact, C2238/αANP induces a
significant downregulation of ApoE which plays an important
role on atherosclerosis development.19,20 ApoE is a 34-kDa
protein that participates in the mobilization and distribution of
cholesterol and of other lipids among various tissues of the
body.20 It is known that ApoE deficiency alone promotes the
development of aortic atherosclerotic plaques in mice.21
Previous studies demonstrated that ApoE exerts also pleio-
tropic antiatherosclerotic and anti-inflammatory cellular
effects. ApoEwas previously found to be expressed in VSMCs
where ApoE downregulation is positively correlated with
typical markers of inflammation such as Smad422 and NF-κ
B.23 In addition, ApoE hampers the proinflammatory functions
of inflammatory cells.24 In humans, where lack of ApoE is rare,
risk of atherosclerosis is strongly associated with three
common apoE isoforms in the order of APOE44APOE34
APOE2.20 Furthermore, ApoE is known to play a role in the
development of both cardiovascular25 and neurological
diseases.26 Therefore, our study may suggest that C2238/
αANP induces cellular abnormalities through the inhibition of
the above-described pleiotropic effects of ApoE. Furthermore,
since higher myeloperoxidase levels were reported in Apo− /−
mice,27 we can postulate that C2238/αANP may, at least in
part, associate to higher myeloperoxidase levels, as pre-
viously reported in coronary artery disease patients,4 through
its ability to lower ApoE gene expression.
On the other hand, our current results indicate that wild-type
αANP may exert physiological antiatherosclerotic effects by
upregulating ApoE levels. This possibility is supported by
previous evidence suggesting a close relationship between
natriuretic peptides (NPs) and atherosclerosis. In fact, NPs are
significantly more expressed in human coronary explants of
advanced atherosclerotic lesions.28 Inhibition of NP degrada-
tion by NEP inhibitor candoxatril prevented fatty deposit in a
rabbit model.29 Circulating NP levels increase in parallel to the
increase of coronary plaque stenosis, reaching a plateau level
at the highest degree of vessel stenosis.30
Notably, previous work has shown that atherosclerosis
increases in an animal model lacking both NPR-A and ApoE
(Npr1− /− ApoE− /− mice),31 suggesting that lack of NPR-A
could induce VSMC growth through other receptor signaling,
thus enhancing the negative vascular effects due to lack
of ApoE.
Another original finding of our study is the demonstration
that C2238/αANP induces ApoE downregulation through
the NPR-C-dependent upregulation of Egr-1. This effect is
mediated by NADPH oxidase activity, since apocynin abro-
gated the effects of C2238/αANP on Egr-1 activation.
To our knowledge, this is the first time that a negative
epigenetic regulation of ApoE by Egr-1 is demonstrated in
the vascular context. This finding also extends previous
evidence advocating a role of Egr-1 activation in the
development of atherosclerosis and may suggest that Egr-1
activation may contribute to atherosclerosis through the
downregulation of ApoE. Interestingly, previous work
demonstrated that atherosclerosis is reduced in a double
knockout model of Egr-1 and ApoE mice, as compared with
that observed in the ApoE− /− knockout model only, thus
suggesting that lack of Egr-1 is protective in the absence of
ApoE.32 Our study extends this evidence by demonstrating
that Egr-1 can be upstream of ApoE, negatively regulating its
expression.
Of note, we found that Egr-1 activation by C2238/αANP
promotes the upregulation of miR199a-3p and miR199a-5p,
thus confirming previous findings demonstrating that Egr-1
regulates miR199a.15 These data suggest that Egr-1 may
epigenetically regulate ApoE through these two microRNAs
(miRNAs). In fact, Pencheva et al.14 have recently demon-
strated that miR199a-3p and miR199a-5p regulate melanoma
metastasis formation through the downregulation of ApoE
levels. The authors found that these miRNAsmay either target
ApoE directly or indirectly inhibit ApoE levels through the
targeting of DNAJA4, a heat-shock protein stimulating ApoE
levels. In line with this evidence, we also found that C2238/
αANP/NPR-C/Egr-1/miR199a signaling promotes the down-
regulation of DNAJA4 levels.
Of note, these findings reinforce available evidence
elucidating the role of miRNAs in the pathogenesis of VSMC
abnormalities and of vascular diseases in general. In this
Figure 2 C2238/αANP induces ApoE downregulation through NPR-C-dependent mechanisms associated with the upregulation of miR199a and of Egr-1 in HUVSMCs. (a)
Analysis by RT-PCR and by western blotting of ApoE expression levels upon CC2238/αANP in NPR-C not silenced and silenced cells. **Po0.0001 for CC2238/αANP versus all
other samples. (b) miR199a-3p, miR199a-5p, DNAJA4 mRNA levels under either TT2238/αANP or CC2238/αANP (upper part of the panel) and in NPR-C not silenced and
silenced cells under CC2238/αANP (lower part of the panel). Two specific siRNAs were used to obtain NPR-C gene silencing. **Po0.0001 for CC2238/αANP versus TT2238/
αANP and CTR. ΔPo0.005 for TT2238/αANP versus CTR and for CC2238/αANP versus CTR (miR199a-3p and miR199a-5p). (c) Representative western blotting of Egr-1,
with corresponding densitometric analysis under either TT2238/αANP or CC2238/αANP exposure (left side) and under CC2238/αANP in NPR-C not silenced and silenced cells
(right side). **Po0.0001 for CC2238/αANP versus all other samples. Results are expressed as mean±S.D. Number of independent experiments= 6. CC2238/αANP, variant
αANP; TT2238/αANP, wild-type αANP; siRNA1, NPR-C gene silencer 1; siRNA2, NPR-C gene silencer 2; hsa-miR199a, human microRNA199a; Egr-1, early growth response
protein-1; CTR, control
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Figure 3 C2238/αANP induces ApoE downregulation through NPR-C-dependent mechanisms associated with the upregulation of miR199a and of Egr-1 in CASMCs.
(a) Analysis by RT-PCR and by western blotting of ApoE expression levels upon CC2238/αANP in NPR-C not silenced and silenced cells. **Po0.0001 for CC2238/αANP versus
all other samples. (b) miR199a-3p, miR199a-5p, DNAJA4 mRNA levels under either TT2238/αANP or CC2238/αANP (upper part of the panel) and in NPR-C not silenced and
silenced cells under CC2238/αANP (lower part of the panel). Two specific siRNAs were used to obtain NPR-C gene silencing. **Po0.0001 for CC2238/αANP versus TT2238/
αANP and CTR. ΔPo0.005 for TT2238/αANP versus CTR and for CC2238/αANP versus CTR (miR199a-3p and miR199a-5p). (c) Representative western blotting of Egr-1,
with corresponding densitometric analysis under either TT2238/αANP or CC2238/αANP exposure (left side) and under CC2238/αANP in NPR-C not silenced and silenced cells
(right side). **Po0.0001 for CC2238/αANP versus all other samples. Results are expressed as mean± S.D. Number of independent experiments= 6. For abbreviations see
Figure 2
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regard, we previously found that a dysregulation of miR21
contributed to VSMC derangements upon C2238/αANP
stimulation.11 In addition, downregulation of miR23b in injured
vascular wall was recently found to modulate VSMC
phenotypic switching through the involvement of both SMAD3
and FOXO4.33 Overall, this evidence supports the knowledge
that miRNA-dependent epigenetic mechanisms can regulate
the pathogenesis of human diseases in a highly integrative
manner.
Previous deliveries of human ApoE3 by intramuscular
plasmid injection and adenovirus,34 by synthetic apolipopro-
tein mimetic peptides35 or by a cell-based platform,36 have
inhibited the development of atherosclerotic lesions. We first
assessed the specific ApoE isoform expressed by the two
VSMC lines used in our studies, which was never reported
before. Consequently, we observed full benefits from the
exposure of VSMCs to the specific recombinant ApoE isoform,
despite the presence of C2238/αANP. The pleiotropic effects
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Figure 4 Impact of Egr-1 gene silencing on the ApoE regulatory pathway in both HUVSMCs and CAMSCs. (a) Impact of Egr-1 gene silencing on Egr-1, miR199-3p, miR199-
5p, DNAJA4 expression levels (as detected by RT-PCR) and on ApoE expression levels (as detected by both RT-PCR and western blotting) in HUVSMCs. Two specific siRNAs
were used to obtain Egr-1 gene disruption. (b) Impact of Egr-1 gene silencing on Egr-1, miR199-3p, miR199-5p, DNAJA4 expression levels (as detected by RT-PCR), and on
ApoE expression levels (as detected by both RT-PCR and western blot) in CASMCs. Results are expressed as mean± S.D. Number of independent experiments= 4 for each cell
lines. **Po0.0001 for CC2238/αANP versus all other points. siRNA1, Egr-1 gene silencer 1; siRNA2, Egr-1 gene silencer 2; for other abbreviations see Figures 2 and 3
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Figure 5 Effect of recombinant ApoE on cell viability in the presence of CC2238/αANP in both HUVSMCs (a) and in CASMCs (b) Cells were concomitantly exposed to
recombinant ApoE and CC2238/αANP. At the end of stimulation, cell viability was analyzed by FACS. Each figure panel shows representative scatter plots for each experimental
condition (left side) and corresponding densitometric analysis (right side). Results are expressed as mean± S.D. Number of independent experiments= 3 for each ApoE isoform.
**Po0.0001 for CC2238/αANP versus all other points. CC2238/αANP, variant αANP; CTR, control; PI, propidium iodide; ApoE, apolipoprotein E; CTR, control
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Figure 6 Effect of recombinant ApoE on markers of inflammation in the presence of CC2238/αANP in both HUVSMCs (a) and CASMCs (b). Cells were concomitantly
exposed to recombinant ApoE and CC2238/αANP. Twenty-four hours after completion of stimulation, total proteins were analyzed for markers of inflammation by western blot.
(a) Representative western blot of Nf-κB and Smad4, with corresponding densitometric analysis, in HUVSMCs. (b) Representative western blot of Nf-κB and Smad4, with
corresponding densitometric analysis, in CASMCs. Data are expressed as mean± S.D. Number of independent experiments= 3 for each ApoE isoform. **Po0.0001 for
CC2238/αANP versus all other points. CC2238/αANP, variant αANP; ApoE, apolipoprotein E; CTR, control
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of ApoE can well explain our results, since this protein is
atheroprotective not only through its lipid-lowering effect
but also through antioxidant and anti-inflammatory
activities.19 The beneficial results obtained through
ApoE treatment of damaged VSMCs exposed to C2238/
αANP highlight the potential key role of this molecule in the
treatment of atherosclerosis in subjects with C2238/αANP
variant, although several limitations still exist for its clinical
application.
In summary, we report the first evidence of a novel
vascular disease mechanism in VSMCs mediated by
NPR-C, involving Egr-1 and two dependent small noncoding
RNAs, ultimately leading to ApoE downregulation, in the
presence of the C2238/αANP gene variant, an emerging
cardiovascular risk factor. This newly discovered transduction
cascade contributes to the wide range of damaging vascular
actions due to C2238/αANP that are in contrast with the known
beneficial properties of wild-type αANP. Moreover, our novel
findings discover unknown pleiotropic actions of NPR-C in
vascular cells through its involvement in the epigenetic
regulation of vascular antiatherosclerotic proteins, such as
apolipoprotein E.
Materials and Methods
Stimulation of HUVSMCs with TT2238 and CC2238/αANP
and RNA extraction for the atherosclerosis macroarray analysis.
Commercially available HUVSMCs were stimulated with either synthetic wild
type (TT2238) or mutant (CC2238)/αANP at a final concentration of 109 mol/l for
12 h, as previously described.9–11 Control plates received αANP-free medium.
Three experiments were performed. Total RNA, obtained at the end of stimu-
lation, was used for cDNA synthesis and then for the macroarray analysis.
Confirmation of ApoE gene and protein modulation upon CC2238/αANP and
TT2238/αANP was subsequently obtained in independent experiments in
HUVSMCs and also in CASMCs (number of experiments= 6 for each cell line)
by RT-PCR, based on SYBR Green methodology, and by western blotting of
total proteins.
Impact of NPR-C gene silencing on modulation of ApoE gene
and protein upon CC2238/αANP. HUVSMCs and CASMCs stimulation
with CC2238/αANP was repeated both in the presence and in the absence of
NPR-C (number of experiments= 6) to verify the role of this receptor in mediating
the effects of CC2238/αANP on ApoE gene and protein expression levels,
according to our previous reports.10,11
Role of NPR-C-dependent activation of miRNA199a-3p and
miRNA199a-5p in the modulation of ApoE by CC2238/αANP.
Involvement of Egr-1. To verify if a known epigenetic modulation of ApoE,
dependent on miRNA199a-3p and 199a-5p,14 played a role in our experi-
mental context, total RNA, extracted from both NPR-C not silenced and silenced
HUVSMCs and CASMCs, was purified to isolate small RNAs by using a com-
mercially available kit. For RT-PCR of DNAJA4, a known target of miRNA199a,14 a
TaqMan gene expression assay was used. Next, based on previous knowledge that
miRNA199a expression levels are modulated by Egr-1,15 we assessed the Egr-1
protein expression level upon either TT2238/αANP or CC2238/αANP by western
blotting. We also better established the role of Egr-1 into the ApoE modulation
under CC2238/αANP with additional experiments. First, the known role of
oxidative stress on Egr-1 stimulation17 was verified by exposing VSMCs to CC2238/
αANP both in the absence and in the presence of apocynin (number of
experiments= 3), following conditions previously described.9 Egr-1 expression
levels were therefore assessed by western blotting. Subsequently, modulation of
both miRNA199a-3p and miRNA199a-5p, of DNAJA4 and of ApoE was
determined in Egr-1 silenced VSMCs exposed to CC2238/αANP (number of
experiments= 4).
Assessment of cleaved caspase-3, CREG, JNK, p38MAPK, Nf-
kBp65 and TGFβ (Smad4) expression levels as markers of
apoptosis, necrosis and inflammation upon CC2238/αANP both
in the presence and in the absence of NPR-C. To verify whether
downregulation of ApoE expression in our experimental conditions was as-
sociated, as expected, to increased rate of apoptosis, necrosis and inflammation,13
total proteins were analyzed by using the following specific primary antibodies:
anti-cleaved caspase-3, anti-CREG, anti-phosphoJNK, anti-JNK, anti-phospho-
p38MAPK, anti-p38MAPK, anti-NFκBp65, anti-Smad4, anti-β-actin. The
latter was used as the housekeeping protein. Following incubation with horse-
radish peroxidase-conjugated secondary antibody, signals were revealed as
described below.
Impact of exposure to recombinant ApoE on cell viability,
apoptosis, necrosis and inflammation in both HUVSMCs and
CASMCs in the presence of CC2238/αANP. To test the ability of ApoE
supplementation to rescue the harmful effects induced by CC2238/αANP, and
based on sequencing results of specific ApoE isoforms expressed in the two cell
lines, HUVSMCs were exposed for 12 h to CC2238/αANP and either recombinant
ApoE2 or ApoE3 protein (10 μg/ml; Sigma). CAMSCs were exposed to CC2238/
αANP and either recombinant ApoE3 or ApoE4 protein (10 μg/ml; Sigma).
Recombinant proteins for ApoE were added to VSMCs as previously described.37
Figure 7 Schematic representation of the pathway involving NPR-C, Egr-1,
miR199a-3p and miR199a-5p on ApoE modulation upon CC2238/αANP exposure in
VSMCs. The positive effects of ApoE supplementation to VSMCs, despite CC2238/
αANP exposure, support the strong contribution of this pathway into promotion of
vascular damage through the final ApoE downregulation. C2238/αANP, variant
αANP; NPR-C, type C natriuretic peptide receptor; ROS, reactive oxygen species;
Egr-1, early growth response protein-1; miR199a, microRNA199a; CREG, cellular
repressor of E1A-stimulated gene; JNK, c-Jun N-terminal kinase
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Twenty-four hours after completion of exposure to CC2238/αANP and the specific
recombinant ApoE isoform, counting of apoptotic cells was performed by flow
cytometry analysis (FACS) and total proteins were extracted for western blotting
analysis of Nf-κBp65 and Smad4.
Experiments were performed in triplicate for each ApoE isoform.
Cells culture. Commercially available HUVSMCs, purchased from ATCC
(American Type Culture Collection; Manassas, VA, USA), were grown in Kaighn's
F12 medium containing 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, and
supplemented with 0.1 mg/ml heparin, 0.03 mg/ml endothelial cell growth
supplement, 10% fetal bovine serum. Commercially available CASMCs (purchased
from Lonza, Walkersville, MD, USA) were grown in Smooth Muscle Growth Medium-
2 (SmgM-2; Lonza). Four batches were used for each cell line to perform all
experiments.
Cells were used within the fifth passage and at 70% confluence. For stimulation
with either TT2238 or CC2238/αANP, they were seeded in 24-well plates (8 × 104
cells/well), cultured in their respective growth medium for 24 h, subsequently starved
and stimulated with αANP at a final concentration of 109 mol/l for 12 h in the presence
of 10% fetal calf serum. Control plates received αANP-free medium.
Total RNA extraction. Total RNA was obtained using Trizol reagent
(Life Technologies, Carlsbad, CA, USA), subjected to DNAse I treatment (Qiagen,
Venlo, Netherlands) and subsequently purified using RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. RNA integrity was assessed by
denaturing agarose gel electrophoresis and its concentration was verified by using
NanoDrop2000c UV-Vis spectrophotometer (Thermo Scientific, Waltham, MA USA).
RT-PCR macroarray analysis. Three experiments were carried out with
each stimulus and RNA was pooled for the macroarray analysis. Two micrograms of
total RNA were used for cDNA synthesis using RT2 First Strand Kit (Qiagen). We
carried out quantitative RT-PCR macroarray analysis using a Human Athero-
sclerosis RT2Profiler PCR Array purchased from Qiagen. Experiments were per-
formed as previously described.9 Briefly, cDNA template was mixed with one of
ready to use RT2 Real-Time SYBR Green PCR Master Mix (Qiagen). The chosen
array contains a panel of 84 primer sets for pathway-focused genes (human
atherosclerosis), five housekeeping genes and three RNA and PCR quality controls.
The mixture was aliquoted into each well of the same plate containing predispensed
gene-specific primer sets and PCR was performed on ViiA 7 Real-Time PCR
System (Life Technologies). Experiments were performed in triplicate. Data analysis
was carried out using the PCR Array Data Analysis Web Portal (http://www.
superarray.-com/pcrarraydataanalysis.php) and ΔΔCt method.38 Results were
expressed as relative levels of each gene mRNA under the effect of either CC2238
or TT2238/αANP referred to the expression of this gene in unstimulated cells (that
were chosen to represent 1x expression of each gene). Results were considered
significant when mRNA expression was 5-fold higher or lower than that of
unstimulated cells.
Quantitative RT-PCR of ApoE, NPR-C, Egr-1 (SYBR Green
methodology). Two microliters of cDNA were mixed with 5 μl of SYBR Green
PCR master Mix (Life Technologies) and 0.5 μl of specific primers: ApoE (forward
5′-GAGCAAGCGGTGGAGACAG-3′ and reverse 5′-CATCAGCGCCCTCAGTTCC
-3′); NPR-C (forward 5′-GGAAGACATCGTGCGCAATA-3' and reverse 5'-GATGCT
CCGGATGGTGTCA-3'); Egr-1 (forward 5′-ACCGCAGAGTCTTTTCCTGACA-3′
and reverse 5′-GGTGCAGGCTCCAGGGAAAA-3′).
β-Actin was used as the housekeeping gene (forward 5′-GCAAGAGATGGC
CACGGCTG-3′ and reverse 5′-CCACAGGACTCCATGCCCAG-3′). RT-PCR was
carried out on the ViiA 7 Real-Time PCR System with cycling conditions of 50 °C
for 2 min, 95 °C for 10 min followed by 95 °C for 15 s and 60 °C for 60 s for a total
of 40 cycles. Measurements were performed in triplicate in each assay.
Results were expressed as relative levels of each gene mRNA as compared with
control cells.
Quantitative RT-PCR of miRNA199a-3p, miRNA199a-5p, DNAJA4
(TaqMan methodology). Total RNA was purified to isolate small RNAs with a
specific kit (miRNeasy Mini Kit; Qiagen) according to the manufacturer’s in-
structions. For cDNA synthesis of miR199a-3p, miR199a-5p and control miRU87,
1 μg of purified RNA was mixed with 3 μl of NCode VILO miRNA cDNA Synthesis
Kit (Life Technologies) and 1 × RT-primer (Life Technologies) in a total reaction
volume of 20 μl. Reaction was incubated at 16 °C for 30 min, 42 °C for 30 min and
85 °C for 5 min in a T-100 Thermal Cycler (Bio-Rad, Hercules, CA, USA). Then, 2 μl
of the RT reaction was added to 1 μl of a specific TaqMan MicroRNA Assay 20 ×
(miR199a-3p, miR199a-5p, miRU87; Life Technologies) and 10 μl of TaqMan
Universal PCR Master Mix II with UNG (Life Technologies) in a 20 μl final volume.
RT-PCR was performed using the ViiA 7 Real-Time PCR System with cycling
conditions of 95 °C for 10 min followed by 95 °C for 15 s and 60 °C for 60 s for a
total of 40 cycles. Each TaqMan assay was run in triplicate. Results were expressed
as relative levels of each miRNA under the effect of different treatments relative to
unstimulated cells.
For RT-PCR of DNAJA4, 2 μl of cDNA were mixed with 10 μl of TaqMan Universal
Master Mix II with UNG and 1 μl of DNAJA4 TaqMan Gene Expression Assay
(Life Technologies) in a 20 μl final volume. β-Actin was used as the housekeeping
gene. RT-PCR was performed using ViiA 7 Real-Time PCR System with cycling
conditions of 50 °C for 2 min, 95 °C for 10 min followed by 95 °C for 15 s and 60 °C
for 60 s for a total of 40 cycles. Each assay was run in triplicate. Results were
expressed as mRNA levels under the effect of different treatments relative to
unstimulated cells.
Total proteins extraction and western blotting. Total proteins were
extracted from cells 24 h after completion of either TT2238/αANP or CC2238/αANP
exposure. Samples were lysed in 1 : 10 weight/volume in lysis buffer (50 mM NaCl,
100 mM Tris-HCl pH 7.4, 1 mM ethylenediaminetetracetic acid (EDTA), 1% SDS)
supplemented with protease and phosphatase inhibitors (Sigma Aldrich,
Saint Louis, MO, USA), incubated on ice for 15 min. and centrifuged at 13 000 r.
p.m. for 15 min. Protein concentration was determined by DC Protein Assay Kit
(Bio-Rad) following the manufacturer’s instructions. Protein lysates were boiled at
95 °C for 5 min in the presence of gel loading buffer (Bio-Rad). Fifty micrograms of
each sample were loaded on 10% SDS-polyacrylamide gel and run for
120 min at 100 V. Proteins were then transferred onto polyvinylidene difluoride
membranes (PVDF; Bio-Rad) using the Trans-Blot Turbo Transfer System
(Bio-Rad). Nonspecific binding sites were blocked at room temperature for 1 h in
5% bovine serum albumin in Tris-buffered saline buffer with 0.1% Tween 20 (Sigma)
(TBS-T). Membranes were incubated at 4 °C overnight with the following primary
antibodies:
anti-ApoE (1 : 1000; Millipore, Temecula, CA, USA), anti-Egr-1 (1 : 1000; Cell
Signaling, Danvers, MA, USA), anti-phosphoJNK (1 : 200; Santa Cruz Laboratories,
Santa Cruz, CA, USA), anti-JNK (1 : 200; Santa Cruz), anti-phospho-p38MAPK
(1 : 200; Santa Cruz), anti-p38MAPK (1 : 200; Santa Cruz), anti-NFκBp65 (1 : 200;
Santa Cruz), anti-cleaved caspase-3 (1 : 1000; Cell Signaling), anti-Smad4 (1:1000;
Cell Signaling); anti-CREG (1:1000; R&D System, Minneapolis, MN, USA),
anti-β-actin (1 : 1000; Santa Cruz).
Following three washes of 10 min in TBS-T, membranes were incubated for 1 h at
room temperature with 1 : 5000 horseradish peroxidase-conjugated donkey anti-goat
(for ApoE) or goat anti-mouse or goat anti-rabbit secondary antibodies diluted in
TBS-T. After three washes of 10 min in TBS-T, signals were revealed
with an enhanced chemiluminescence detection system (Luminata Crescendo;
Millipore, Darmstadt, Germany) and the immunoreactivity of bands was
visualized using ChemiDoc XRS+Imaging System (Bio-Rad). Protein bands were
scanned and quantified densitometrically. They were finally normalized using β-actin
levels.
NPR-C and Egr-1 gene silencing. NPR-C and Egr-1 gene silencing was
performed with specific siRNAs (Mission siRNA; Sigma) by following conditions
previously described.10,11 Twenty-four hours after transfection, both silenced and not
silenced cells were exposed to CC2238/αANP for 12 h and subsequently extracted
for total RNA and total proteins. Efficiency of gene silencing was assessed by
RT-PCR, following conditions described above.
Role of oxidative stress in the Egr-1 induced increase by
CC2238/αANP. The known role of oxidative stress on Egr-1 stimulation 17
was verified by exposing VSMCs to CC2238/αANP both in the absence and in the
presence of apocynin, following conditions previously described.9 Egr-1 expression
levels were therefore assessed by western blotting.
Sequencing of apoE gene expressed in HUVSMCs and CASMCs.
Genomic DNA was isolated from both HUVSMCs and CASMCs using a
commercially available kit (Qiagen, Chicago, IL, USA). In order to identify the
three allelic forms of human ApoE gene (allele ε2, ε3, ε4) PCR reactions were set
up by using a specific pair of primers: forward 5′-CTCCCACTGTGCGACACC-3′,
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reverse 5′-CTGCTCCTTCACCTCGTCC-3′. DNA was first amplified by PCR with 40
cycles at an annealing temperature of 55 °C using a T-100 Thermal Cycler
(Bio-Rad). Following purification of the PCR product (562 bp) with MinElute
PCR purification kit (Qiagen), sequence reactions were prepared using the Big Dye
Terminator v3.1 cycle sequencing Kit (Applied Biosystems, Carlsbad, CA, USA).
Unincorporated dye terminators from sequencing reactions were removed using
DyeEx 2.0 Spin kit (Qiagen). Purified fragments were electrophoresed on an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems) according to the manufac-
turer's protocol. All sequencing results were compared with those present in the
NCBI databases using BLAST to confirm the allelic variants.
Flow-cytometry analysis. Twenty-four hours after completion of exposure to
CC2238/αANP and the specific recombinant ApoE isoform, counting of
apoptotic cells was performed by FACS using Annexin V-Fitc and propidium iodide
(PI) staining (ImmunoStep, Salamanca, Spain). For this purpose, cells were
harvested by incubation with 1 ml of trypsin/EDTA (Lonza) for 3 min at 37 °C.
Trypsinization was stopped by addition of medium and the suspension was
centrifuged at 1200 r.p.m. for 5 min at 4 °C. Each pellet was washed with cold
phosphate-buffered saline (PBS 1 × ). Then, tubes were vortexed thoroughly and
centrifuged again as before. Cells were gently resuspended and vortexed in binding
buffer at a concentration of 3 × 106 cells/ml. Then, 100 μl of cell suspension was
added to 5 μl of Annexin V and 10 μl of PI. Samples were mixed for 15 min in the
dark at 4 °C and 400 μl of PBS 1x was added to the solution. Ten thousand cells
were analyzed by FACS on a BD Accuri C6 flow cytometer (Biosciences,
Erembodegem-Dorp, Belgium) to count apoptotic cells. Both negative control
(untreated cells) and positive control (cells treated with hydrogen peroxide) were
included in the analysis.
Statistical analysis. Continuous variables are expressed as mean± S.D.
Comparisons between two groups were performed using Student's t-test. When the
analysis was adjusted for the multiplicity of compared groups, one-way ANOVA
followed by Bonferroni post hoc test was performed. Normality of variables
distribution was tested by the Kolmogorov–Smirnov test. GraphPad Software
(San Diego, CA, USA; version 5.0) and SPSS statistical software (SPSS Inc.,
Chicago, IL, USA; version 12.0) were used for statistical analysis. Po0.05 was
considered significant.
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